Log In
person
Vericel Corp
VCEL
summarize
2 total product lines
calendar_month
Revenue as of 12/31/2023
| Reporting Segmentarrow_drop_up | Product Line | Amount (USD) | Percentage |
|---|---|---|---|
| keyboard_arrow_right | Reporting Segment & Product Line | Amount (USD) | Percentage |
| Cell Therapies & Specialty Biologics |
Biologically-Derived Tissue Scaffolding Products; private insurance
These companies manufacture tissue scaffolding products, primarily from placental tissue (such as amniotic membrane allografts) and sell directly to their customers. These are used for skin wound healing and dermal reconstruction. Their products are paid for primarily through private health insurance.
|
197.52M | 100.00% |
| Cell Therapies & Specialty Biologics |
Pre-Revenue Pharmaceuticals
These companies research and develop pharmaceuticals, but do not generate significant revenue. They may eventually market or manufacture their products (pending regulatory approval) or generate revenue through royalties or other means.
|
Non-Attributed |
Non-Attributed
help
Why Zero? Explanation of what the heck's going on here.
|
| keyboard_arrow_down |
Cell Therapies & Specialty Biologics
Biologically-Derived Tissue Scaffolding Products; private insurance
|
197.52M | 100.00% |
| keyboard_arrow_right |
These companies manufacture tissue scaffolding products, primarily from placental tissue (such as amniotic membrane allografts) and sell directly to their customers. These are used for skin wound healing and dermal reconstruction. Their products are paid for primarily through private health insurance.
|
||
| keyboard_arrow_down |
Cell Therapies & Specialty Biologics
Pre-Revenue Pharmaceuticals
|
Non-Attributed |
Non-Attributed
help
Why Zero? Explanation of what the heck's going on here.
|
| keyboard_arrow_right |
help
Why Zero? Explanation of what the heck's going on here.
These companies research and develop pharmaceuticals, but do not generate significant revenue. They may eventually market or manufacture their products (pending regulatory approval) or generate revenue through royalties or other means.
|
||